Structure Therapeutics EBITDA 2022-2025 | GPCR

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Structure Therapeutics ebitda from 2022 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Structure Therapeutics ebitda from 2022 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$229.7B
Amgen (AMGN)	$153.5B
Gilead Sciences (GILD)	$149.5B
Vertex Pharmaceuticals (VRTX)	$96B
Bristol Myers Squibb (BMY)	$93.5B
CSL (CSLLY)	$83.2B
GSK (GSK)	$76.9B
Regeneron Pharmaceuticals (REGN)	$57.9B
Alnylam Pharmaceuticals (ALNY)	$57B
Argenex SE (ARGX)	$39.1B
BioNTech SE (BNTX)	$26.3B
Insmed (INSM)	$23.9B
Royalty Pharma (RPRX)	$20.3B
Biogen (BIIB)	$18.8B
Incyte (INCY)	$15.5B
Illumina (ILMN)	$14.6B
Genmab (GNMSF)	$14.3B
Genmab (GMAB)	$13.5B
Ascendis Pharma (ASND)	$12B
BioMarin Pharmaceutical (BMRN)	$10.9B
QIAGEN (QGEN)	$10.7B
Swedish Orphan Biovitrum (BIOVF)	$10.6B
Exelixis (EXEL)	$10.1B
Moderna (MRNA)	$9.9B
Verona Pharma American Depositary Share (VRNA)	$9B
Blueprint Medicines (BPMC)	$8.3B
Bio-Techne Corp (TECH)	$7.9B
Halozyme Therapeutics (HALO)	$7.7B
Exact Sciences (EXAS)	$7.7B
Roivant Sciences (ROIV)	$7.6B